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INTRODUCTION
Vascular endothelial growth factors (VEGFs) and their tyrosine
kinase receptors (VEGF-Rs) are central regulators of tumor angio-
genesis and lymphangiogenesis. The VEGF family of growth factors
include five members in mammals : VEGF (or VEGF-A), placenta
growth factor (PlGF), VEGF-B, VEGF-C and VEGF-D. The VEGF
ligands bind to three transmembrane tyrosine kinase receptors,
VEGF-R1/Flt1, VEGF-R2/KDR and VEGF-R3/Flt4 (1-3).
VEGF is a crucial therapeutic target in cancer therapy because
of its critical role in the induction of tumor angiogenesis (1-3). Sev-
eral angiogenesis inhibitors targeting the VEGF-VEGF receptor
pathway have been developed and become an important option for
management of a number of human malignancies, including col-
orectal cancer. Unfortunately, a significant number of patients do
not respond to VEGF-targeted therapy. Furthermore, the vast ma-
jority of patients who initially respond to anti -VEGF therapy will
develop resistance (4-8). Therefore, inherently resistant and de-
velop acquired resistance to the VEGF-pathway inhibitors is a
growing concern in the clinic.
Mechanisms of the resistance include up-regulation of alternative
pro-angiogenic factors (FGF-2, HGF and IL-8) and protection of
the tumor vasculature either by recruiting proangiogenic proinflam-
matory cells or by increasing protective pericyte coverage (4-7). In
addition to these proposed mechanisms, oncologists have begun
to focus on the mechanisms of direct action of anti -VEGF agents
on cancer cells, i.e., actions that are independent of the antiangi-
ogenic effects of VEGF inhibitors, and tumor adaptation to VEGF
inhibition (5).
In fact, VEGF-R is expressed not only in endothelial cells but
also in several cancer cell lines, including colorectal, bladder, breast,
and pancreatic cancer cells (9-13). In addition, an immunohisto-
chemical screen of non-endothelial cancer specimens revealed de-
tectable levels of VEGF-Rs in CRC, bladder, breast, and lung can-
cers (14). These observations suggested a possible autocrine/
paracrine VEGF signaling pathway within cancer cells. Indeed, it
has become clear that VEGF acts as an autocrine growth and sur-
vival factor for cancer cells that express VEGF-R (9-13). Thus,
some of the effects observed with anti -VEGF therapies could result
from “direct” effects on tumor cells.
However, the direct effects of anti -VEGF therapy on tumor cells
are not yet fully understood. In this study, we examined the direct
effects of VEGF-targeting agents on tumor cell phenotype. We also
compared the effects on tumor cells between anti -VEGF neutral-
izing monoclonal antibody (anti -VEGF mAb, blockade of VEGF
alone) and VEGF-R tyrosine kinase inhibitor foretinib (blockade
of all VEGF family ligands ; VEGF, VEGF-B, PlGF and VEGF-C).
We found that chronic exposure of colon cancer HCT116 cells to
anti -VEGF mAb resulted in a resistance to hypoxia- induced apop-
tosis. Intriguingly, chronic exposure to foretinib induced not only
a marked resistance to hypoxia- induced apoptosis, but also en-
hancement of migration activity. These results provide a new in-
sight into the adaptation of colon cancer cells to the loss of VEGF
signaling.
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MATERIALS AND METHODS
Cell culture and treatment
Human colon cancer cell line (HCT116) was maintained in
RPMI1640 medium with 10% fetal bovine serum and antibiotics.
To develop the HCT/mAb and HCT/fore cell lines, HCT116 cells
were chronically exposed to anti -VEGF mAb (10μg/ml, R&D Bio-
systems) or VEGF-R tyrosine kinase inhibitor (10 nM foretinib,
Selleckchem) for 60 days in RPMI1640 medium with 10% fetal bo-
vine serum and antibiotics.
Hypoxic treatment and HIF-1α-dependent transcriptional activity
For hypoxic culture conditions, cells were incubated at low con-
fluence and 37 in BBL GasPak 100 anaerobic system in which O2
was 0.2% (BD Biosciences). Hypoxic treatment was functionally
confirmed by transactivation of HIF-1α using a HIF-1α -dependent
reporter construct combined with internal control reporter construct
(Cignal HIF reporter assay kit, SA Biosciences).
Quantitative RT-PCR (qRT-PCR)
The levels of transcripts for VEGF ligands (Vegf-a , Vegf-b , and
Plgf ), VEGF receptors (Vegfr1 and Vegfr2), β -actin were measured
by real time (RT)-PCR using the following specific primer sets :
Vegf-a , 5-GAGCCTTGCCTTGCTGCTCTAC-3(forward) and 5-
CACCAGGGTCTCGATTGGATG-3(reverse) ; Vegf-b , 5-CTGG-
CCACCAGAGGAAAGT-3(forward) and 5-CATGAGCTCCACA-
GTCAAGG-3(reverse) ; Plgf , 5-GGCTGTTCCCTTGCTTCC-3
(forward) and 5-CAGACAAGGCCCACTGCT-3(reverse) ; Vegfr1 ,
5-AGAACCCCGATTATGTGAGAAA-3(forward) and 5-GATA-
GATTCGGGAGCCATCC-3(reverse) ; Vegfr2 , 5-GAACATTTG-
GGAAATCTCTTGC-3(forward) and 5-CGGAAGAACAATGTA-
GTCTTTGC-3(reverse) ; β -actin, 5-CCAACCGCGAGAAGATG-
A-3(forward) and 5-CCAGAGGCGTACAGGGATAG-3(reverse).
Amplification and quantification of the PCR products were per-
formed using the Applied Biosystems 7500 System (Applied Bio-
systems). Standards were run in the same plate and the relative
standard curve method was used to calculate the relative mRNA
expression. RNA amounts were normalized against the β -actin
mRNA level.
Assessment of apoptosis
Apoptotic cells were assessed by a DeadEnd TUNEL-staining
kit (Promega), as previously described (23).
Cell migration and invasion assay
Migration assay was conducted as described by Fan et al (9)
with minor modifications. Equal numbers (50,000 cells per well)
of cells were suspended in 0.25 ml of 1% RPMI1640-FBS without
or with anti -VEGF mAb or foretinib and placed in the top com-
partment of a 8 μm pore membrane chambers (BD Biosciences) ;
0.75 ml of 10% RPMI1640-FBS was added to the bottom compart-
ment. Following 24-h incubation under standard conditions (37/
5% CO2), non-migrating cells were scraped from the top compart-
ment, and cells that had migrated to the bottom compartment were
fixed and stained using the Hemacolor Rapid staining of blood
smear (Merck). Membranes were excised and mounted on a stan-
dard microscope slide. The numbers of migrated cells were deter-
mined from five random high-power fields visualized at200 mag-
nification.
Invasion assays were done using a similar protocol with minor
modifications. The inserts used in the invasion assays were coated
with Matrigel (BD Biosciences) and prehydrated with 1% FBS-
supplemented medium for 2 hours before the addition of the cell
suspension. Following 48-h incubation under standard conditions
(37/5% CO2), and the numbers of invading cells were again quan-
tified.
Statistical analysis
Results are expressed as meansS.D. Statistical analyses of data
were done using ANOVA and the Scheffé’s test. P values0.05
was considered significant.
RESULTS
Effect of chronic treatment with anti-VEGF mAb or foretinib on
the expression of VEGF family members
It has been demonstrated that blockade of VEGF by anti -VEGF
mAb redundantly increase in expression of VEGF family members
(12). Thus, we first examined whether chronic loss of VEGF sig-
nalling (VEGF alone by anti -VEGF mAb or all of VEGF ligands by
foretinib) induces the redundant expression of VEGF family mem-
bers. To adapt to the VEGF inhibitors, HCT116 cells were chroni-
cally treated for 60 days with anti -VEGF mAb (HCT/mAb), with
foretinib (HCT/fore), or without any treatment (HCT/par). The
expression levels of VEGF ligands (VEGF, PlGF and VEGF-B) and
VEGF-Rs (VEGF-R1 and -R2) were measured by RT-qPCR. HCT/
mAb cells increased the expression of all of VEGF ligands and
VEGF-Rs tested (approximately 2- to 2.5 - fold) relative to the con-
trol HCT/par cells (Figure 1A-E). In contrast, HCT/fore cells did
not increase all VEGF ligands and receptors tested (Fig. 1A-E).
Intriguingly, HCT/fore cells, but not HCT/mAb cells, increased
Figure 1. Effect of chronic exposure with anti -VEGF mAb or foretinib
on VEGF family and FGF-2 expression.
HCT116 cells were chronically treated with vehicle (HCT/par) or with
anti -VEGF mAb (HCT/mAb) or foretinib (HCT/fore) for 90 days. Ex-
pression levels of VEGF (A), PlGF (B), VEGF-B (C), VEGF-R1 (D),
VEGF-R2 (E), and FGF-2 (F) were measured by quantitative RT-PCR
(n=4-5, meansS.D.). *P0.01., compared with control HCT/par cells.
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αFGF-2 expression (Fig. 1F) that is well characterized as pro-angio-
genic factor under VEGF-inhibited conditions (5). These results
suggest that prolonged blocking of all VEGF family switched VEGF-
dependent phenotype to VEGF-independent one.
Effect of chronic treatment with anti-VEGF mAb or foretinib
on hypoxia-induced apoptosis
As one of the major in vivo effects of VEGF inhibition is anti -
angiogenesis and its contribution to tumor hypoxia, we examined
sensitivity to hypoxia- induced apoptosis in HCT/mAb and HCT/
fore cells. After exposure to hypoxic conditions (0.2% O2) for 48
h, control HCT/par cells displayed a heightened degree of apop-
tosis (Fig. 2A). HCT/mAb showed a resistance to hypoxia- induced
apoptosis (Fig. 2A). HCT/fore cells exhibited a marked resistance
to the apoptosis, compared with HCT/mAb cells.
To explore how HCT/mAb and HCT/fore cells became resistant
to hypoxia- induced apoptosis, we focused on HIF-1α, since HIF-
1α is a critical regulator of many hypoxia responses, including re-
sistance to apoptosis (15, 16). We confirmed that HIF-1α transcrip-
tional activity under hypoxic conditions was significantly increased
in HCT/mAb and HCT/fore cells compared with control HCT/par
cells (Fig. 2B). We used a HIF-1α inhibitor (FM19G11) that effec-
tively inhibited HIF-1α transcriptional activity under hypoxic condi-
tions in HCT/par, HCT/mAb and HCT/fore cells (Fig. 2B, gray
bar). Inhibition of HIF-1α activity in HCT/mAb cells significantly
increased hypoxia- induced apoptosis. However, blocking of HIF-
1α activity in HCT/fore cells did not increase hypoxia- induced
apoptosis (Fig. 2C, gray bar).
Effect of chronic treatment with anti-VEGF mAb or foretinib
on cell migration and invasion
We then assessed the effects of anti -VEGF mAb or foretinib on
cell migration activity. HCT/mAb cells showed a slight increase in
migration compared with the control HCT/par cells (Fig. 3A, B).
By contrast, HCT/fore cells showed 10-fold increase in migration
activity (Fig. 3A, B).
Figure 2. Effect of chronic exposure with anti -VEGF mAb or foretinib
on hypoxia - induced apoptosis.
(A) Cells were exposed to hypoxia (0.2% O2) for 48 h, then apoptotic
cells were determined by TUNEL assay (n=4-5, meansSD). *P
0.01., compared with control HCT/par cells.
(B) Transcriptional activity of HIF-1α under hypoxic conditions with-
out (none) or with HIF-1 inhibitor. Cells were transfected with a HIF-
1α -dependent reporter construct (LucF) and a internal control reporter
plasmid (LucR), then they were exposed to hypoxia (0.2% O2) for 24 h.
The transcriptional activity of HIF-1α was determined by a dual luciferase
assay (n=4, meansSD). *P0.01., compared with control HCT/par
cells.
(C) Cells were exposed to hypoxia (0.2% O2) for 48 h in the absence
(none) or presence of HIF-1 inhibitor, then apoptotic cells were deter-
mined by TUNEL assay (n=6, meansSD). *P0.01., compared with
the respective control cells (none) in each group.
Figure 3. Effect of chronic exposure with anti -VEGF mAb or foretinib
on migration and invasion activity.
(A) HCT/par, HCT/mAb and HCT/fore cells were used for transwell
migration assay (n=4, meansSD). HPF, high power field. *P0.01.,
compared with control HCT/par cells.
(B) Photographs of migrated cells.
(C) HCT/par, HCT/mAb and HCT/fore cells were used for transwell
invasion assay (n=4, meansSD). *P0.01., compared with control
HCT/par cells.
(D) Photographs of invaded cells.
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We also examined the effects of anti -VEGF mAb or foretinib on
cell invasion activity. In agreement with migration activity, HCT/
fore cells showed an increased invasion activity (Fig. 3C, D). There
was no difference in a low invasion activity between HCT/mAb
and HCT/par cells (Fig. 3C, D).
DISCUSSION
This study focused on the direct and chronic effects of VEGF
inhibition on tumor cells using two cell models (HCT/mAb cells
and HCT/fore cells). We found that chronic inhibition of VEGF
alone resulted in resistance to hypoxia- induced apoptosis, while
chronic blockade of all VEGF ligands induced more aggressive
phenotypes (not only apoptotic resistance but also migration/inva-
sion phenotype).
In response to chronic blockade of VEGF, redundant expression
of VEGF family members (VEGF, PlGF, VEGF-B, VEGF-R1 and -
R2) was observed in HCT/mAb cells. Many studies have similarly
shown that inhibition of VEGF signaling in vitro or in vivo leads to
compensatory increases in the expression of VEGF family ligands
(5, 12). By contrast, chronic blockade of all VEGF ligands signal-
ing by foretinib did not show the redundancy, suggesting that HCT/
fore cells acquire VEGF-independent phenotype. In fact, HCT/
fore cells, but not HCT/mAb cells, increased expression of other
pro-angiogenic factor FGF-2.
Both HCT/mAb and HCT/fore cells acquired an apoptosis re-
sistance induced by hypoxic stress. One of possible adaptive
mechanisms may involve a HIF-1α activation. Many studies have
established critical roles for HIF-1α in tumor cell survival and
malignancy : i) HIF-1α is involved in repression of hypoxia- induced
apoptosis in vitro (16) ; ii) HIF-1α plays important roles in resis-
tance to VEGF inhibitor (17-19). In agreement with these reports,
HCT/mAb cells required HIF-1α activation for their resistance to
apoptosis. However, HCT/fore cells did not require HIF-1α, sug-
gesting that HCT/fore cells activate other adaptive pathway that
has yet remained undefined.
Based on the present data and recent reports, it is possible that
anti -VEGF therapies directly inhibit VEGF signaling in tumor cells,
which may remodel tumor cell survival signal(s). In fact, recent
report clearly showed that VEGF suppresses migration of tumor
cells in vitro (21) ; inhibition of VEGF signaling conversely acceler-
ated migration and invasion in vivo (21). These findings suggest
that over the long term inhibition of VEGF, such remodeling re-
sults in adaptation to VEGF inhibition, and this adaptive response
may represent one of potential mechanism of acquired resistance
to anti -VEGF therapies.
VEGF initially held great promise as a therapeutic target. In fact,
VEGF-targeting therapy has been shown to be very effective in
certain tumor types, such as renal cell carcinoma (22, 23). How-
ever, the overall benefit of blocking VEGF activity in other solid
tumors is marginal and has led to some skepticism in the field.
Therefore, molecular mechanism(s) activated by chronic loss of
VEGF signaling will need to be elucidated to improve and further
develop VEGF-targeting therapies.
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